Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Hourican Kevin

2. Date of Event Requiring Statement (MM/DD/YYYY) 6/4/2018

3. Issuer Name and Ticker or Trading Symbol

CVS HEALTH Corp [CVS]

(Last) (First) (Middle)

ONE CVS DRIVE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
EVP & President, CVS Pharmacy /

(Street)

WOONSOCKET, RI 02895

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7709	D
Common Stock (restricted)	1232 ⁽¹⁾	D
Common Stock (restricted)	399 ⁽²⁾	D
Common Stock (restricted)	840 ⁽³⁾	D
Common Stock (restricted)	2444 ⁽⁴⁾	D
Common Stock (restricted)	2146 ⁽⁵⁾	D
Common Stock (restricted)	3523 ⁽⁶⁾	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option	4/1/2014 ⁽⁷⁾	4/1/2020	Common Stock	4426	$54.53	D
Stock Option	4/1/2015 ⁽⁸⁾	4/1/2021	Common Stock	9442	$74.29	D
Stock Option	4/1/2016 ⁽⁹⁾	4/1/2022	Common Stock	17822	$102.26	D
Stock Option	4/1/2017 ⁽¹⁰⁾	4/1/2023	Common Stock	17611	$104.82	D
Stock Option	4/3/2018 ⁽¹¹⁾	4/3/2024	Common Stock	30169	$78.05	D
Stock Option	4/1/2019 ⁽¹²⁾	4/1/2025	Common Stock	87575	$62.21	D

Explanation of Responses:
(1)	Consists of remaining Restricted Stock Units awarded pursuant to Issuer's 2017 Incentive Compensation Plan and its Performance-Based Restricted Stock Unit Plan. Restrictions lapse in three equal installments, commening 2/28/2019.
(2)	Consists of remaining Restricted Stock Units awarded pursuant to Issuer's Performance-Based Restricted Stock Unit Plan, under its 2010 Incentive Compensation Plan. Restrictions lapse 2/28/2019.
(3)	Consists of remaining Restricted Stock Units awarded pursuant to Issuer's Performance-Based Restricted Stock Unit Plan, under its 2010 Incentive Compensation Plan. Restrictions lapse in two equal installments on 2/28/2019 and 2/28/2020.
(4)	Consists of Restricted Stock Units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 4/1/2019.
(5)	Consists of Restricted Stock Units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 4/1/2020.
(6)	Consists of Restricted Stock Units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 4/3/2021.
(7)	Remaining options became exercisable in four equal annual installments beginning on 4/1/2014.
(8)	Remaining options became exercisable in four equal annual installments beginning on 4/1/2015.
(9)	Option became exercisable in four equal annual installments beginning on 4/1/2016.
(10)	Option became exercisable in four equal annual installments beginning on 4/1/2017.
(11)	Option became exercisable in four equal annual installments beginning on 4/3/2018.
(12)	Option becomes exercisable in four equal annual installments beginning on 4/1/2019.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Hourican Kevin ONE CVS DRIVE WOONSOCKET, RI 02895			EVP & President, CVS Pharmacy

Signatures
/s/ Kevin P. Hourican		6/8/2018
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.